Results 11 to 20 of about 7,117 (221)

A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases [PDF]

Journal of Comparative Effectiveness Research
Aim: Real-world evidence comparing healthcare resource utilization (HRU) and costs between ibrutinib and acalabrutinib, two Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL ...
Kerry A Rogers, Benyam Muluneh, Zaina P Qureshi, Jinghua He, Alex Bokun, Zhijie Ding, Marie-Helene Lafeuille, Priyanka Gogna, Bruno Emond, Michael Fradley   +9 more
doaj   +3 more sources

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib [PDF]

Blood
Chronic lymphocytic leukemia (CLL) progression during Bruton tyrosine kinase (BTK) inhibitor treatment is typically characterized by emergent B-cell receptor pathway mutations.
Benrashid, Samon, Byrd, John C, de Bruin, Gerjan, De Jesus, Gary, Ghia, Paolo, Illés, Árpád, Jones, Daniel, Jurczak, Wojciech, Kater, Arnon P, Lai, Richard, Lai, Tzung-Huei, Long, Susan, Mohamed, Nehad, Munugalavadla, Veerendra, Robak, Tadeusz, Rule, Simon, Seymour, John F, Woyach, Jennifer A   +17 more
core   +2 more sources

Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis

Experimental Hematology & Oncology
Ibrutinib and acalabrutinib are both associated with an increased risk of atrial fibrillation (AF); however, the comparative risk of AF between these 2 BTK inhibitors remains largely unknown.
Joachim Alexandre, Jonaz Font, Thibault Lenormand, Sylvain Chantepie, Hippolyte Bardet, Gandhi Damaj, Charles Dolladille, Damien Legallois, Angélique Da-Silva, Paul Milliez, Arnaud Bisson, Laurent Fauchier   +11 more
doaj   +2 more sources

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma [PDF]

Journal of Clinical Oncology
The combination of the Bruton tyrosine kinase inhibitor ibrutinib with bendamustine-rituximab for first-line treatment of mantle cell lymphoma (MCL) prolonged progression-free survival (PFS), but without improvement in overall survival (OS), likely ...
Belada David, Borbényi Zita, Cheah Chan Y, Chu Michael P, Dreyling Martin, Fogliatto Laura, Forsyth Cecily, Jurczak Wojciech, Kahl Brad S, Kollaborációs szervezet: ECHO investigators, Kryachok Iryna, Lesley Robin, Li Yufu, Morawska Marta, Paludo Jonas, Patti Caterina, Ramadan Safaa, Rule Simon, Salek David, Sancho Juan-Manuel, Song Yuqin, Wang Michael, Zhang Jingyang   +22 more
core   +2 more sources

Cumulative review of cardiac failure with acalabrutinib in the treatment of chronic lymphocytic leukemia using data from clinical trials and postmarketing experience. [PDF]

Hemasphere
Bruton tyrosine kinase inhibitors (BTKis) have revolutionized the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). The first ‐ generation BTKi, ibrutinib, has demonstrated efficacy in various CLL/SLL populations 1 – 3 but
Ghia P, Bajwa N, Corry AJ, Jannuru S, Kreuzbauer G, Pareek M.   +5 more
europepmc   +4 more sources

Cost impact of Bruton’s tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia [PDF]

Journal of Comparative Effectiveness Research
Aim: To estimate cost savings associated with covalent Bruton’s tyrosine kinase inhibitor (cBTKi) choice in patients with treatment-naive (TN) and relapsed/refractory (RR) chronic lymphocytic leukemia (CLL) from a Medicare perspective.
Adam S Kittai, Dipen A Patel, Jason Shafrin, Nadine Zawadzki, Vikram S Shetty, Yazan K Barqawi, Joanna M Rhodes   +6 more
doaj   +2 more sources

Efficacy and safety of BTK inhibitors in Richter’s transformation: a systematic review of clinical evidence [PDF]

Frontiers in Oncology
BackgroundRichter’s transformation (RT) is an aggressive progression of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), most commonly to diffuse large B-cell lymphoma (DLBCL). Therapeutic options are limited, and outcomes are poor,
Canan D. Dirican, Folasade Ajayi, Anas Al Mardini, Bolivia Crocete Aloysia Fernandes, Amara Sofia, Venkatesh Gondhi, Hamid Shaaban, Michael Maroules   +7 more
doaj   +2 more sources

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

Journal of Hematology and Oncology, 2016
More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic ...
Ming-Zhi Zhang, Delong Liu
exaly   +3 more sources

Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials [PDF]

Journal of Immunotherapy and Precision Oncology, 2022
Acalabrutinib, a second-generation and more selective Bruton's tyrosine kinase inhibitor, was developed to potentiate efficacy while minimizing ibrutinib-associated side effects.
Thura Win Htut, Myat Min Han, Kyaw Zin Thein   +2 more
doaj   +1 more source

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy. [PDF]

Eur J Haematol
ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Oliva S, Molica S.
europepmc   +2 more sources